ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2017-12-21 08:00 |
ABIVAX nimmt an der 'LifeSci Advisors Corporate Access' Veranstaltung vom 8. - …
|
German | HTML • 6.7 KB | ||
| 2017-12-21 08:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | PDF • 378.5 KB | ||
| 2017-12-21 08:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | PDF • 378.1 KB | ||
| 2017-12-15 08:00 |
ABIVAX prasentiert auf der 8. internationalen Konferenz uber 'HIV Persistence D…
|
German | HTML • 11.0 KB | ||
| 2017-12-07 08:00 |
ABIVAX prasentiert in Plenarsitzung auf der 8. internationalen Konferenz uber '…
|
German | HTML • 9.5 KB | ||
| 2017-12-07 08:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | PDF • 651.8 KB | ||
| 2017-12-07 08:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | PDF • 636.7 KB | ||
| 2017-11-22 08:00 |
ABIVAX prasentiert auf dem Deutschen Eigenkapitalforum 2017
|
German | HTML • 9.8 KB | ||
| 2017-11-22 08:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | PDF • 520.9 KB | ||
| 2017-11-22 08:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | PDF • 525.9 KB | ||
| 2017-11-20 08:02 |
ABIVAX schliet ersten Patienten mit Colitis ulcerosa in klinische Proof-of-Conc…
|
German | HTML • 10.9 KB | ||
| 2017-11-20 08:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | PDF • 565.2 KB | ||
| 2017-11-20 08:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | PDF • 568.7 KB | ||
| 2017-11-14 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | PDF • 294.8 KB | ||
| 2017-10-30 08:02 |
ABIVAX prasentiert auf der BIO-Europe(R) 2017 - 23rd Annual International Partn…
|
German | HTML • 9.3 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
